Joint Formulary & PAD

Guideline Profile : Diabetes Mellitus

Documentation

Drugs

Below are listed all drugs that are used to treat Diabetes Mellitus.

Committee Recommendations (3)

There are SPS resources to support healthcare professionals (HCP) in taking actions to promote the safer use of insulin. It aims to equip HCPs with insights, support, and shared learning, to address practice with insulin that may lead to harm. See link below.

GLP-1 receptor agonists can impact female hormones, including HRT and contraceptives, and reproductive health through various mechanisms.  For further information and advice see links below.

Please see the attached Type 2 Diabetes treatment guidelines and associated documentation. See attached documents for further information.

Guideline Profile

Indication :
Diabetes Mellitus
Keywords :
Sulphonylureas, gliptins, GLP-1, biguanides, insulin, blood glucose monitoring, SMBG, self monitoring of blood glucose, hypoglyceamia, Type II, SICK day rule, TREND,
Brand Names Include :
Metformin, Vipidia, Alogliptin, Gliclazide, Linagliptin, Trajenta, Glipizide, Liraglutide, Glibenclamide, Glimepiride, Tolbutamide, Glucophage, Acarbose, Glucobay, Dapagliflozin, Forxiga, Exenatide, Bydureon, Linagliptin, Jentadueto, Victoza, Neteglinide, Starlix, pioglitazine, Actos, Competact, Repaglinide, Prandin, Saxagliptin, Onglyza, Sitagliptin, Januvia, Janumet, Vildagliptin, Galvus, Eucreas, Komboglyze,
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Supporting Documents :
23